Biomarkers, Validation and Pharmacokinetic-Pharmacodynamic Modelling
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 42 (12) , 997-1022
- https://doi.org/10.2165/00003088-200342120-00001
Abstract
Four elements are crucial to successful pharmacokinetic-pharmacodynamic (PK/PD) modelling and simulation for efficient and effective rational drug development: (i) mechanism-based biomarker selection and correlation to clinical endpoints; (ii) quantification of drug and/or metabolites in biological fluids under good laboratory practices (GLP); (iii) GLP-like biomarker method validation and measurements and; (iv) mechanism-based PK/PD modelling and validation. Biomarkers can provide great predictive value in early drug development if they reflect the mechanism of action for the intervention even if they do not become surrogate endpoints. PK/PD modelling and simulation can play a critical role in this process. Data from genomic and proteomics differentiating healthy versus disease states lead to biomarker discovery and identification. Multiple genes control complex diseases via hosts of gene products in biometabolic pathways and cell/organ signal transduction. Pilot exploratory studies should be conducted to identify pivotal biomarkers to be used for predictive clinical assessment of disease progression and the effect of drug intervention. Most biomarkers are endogenous macromolecules, which could be measured in biological fluids. Many exist in heterogeneous forms with varying activity and immunoreactivity, posting challenges for bioanalysis. Reliable and selective assays could be validated under a GLP-like environment for quantitative methods. While the need for consistent reference standards and quality control monitoring during sample analysis for biomarker assays are similar to that of drug molecules, many biomarkers have special requirements for sample collection that demand a wellcoordinated team management. Bioanalytical methods should be validated to meet study objectives at various drug development stages, and possess adequate performance to quantify biochemical responses specific to the target disease progression and drug intervention. Protocol design to produce sufficient data for PK/PD modelling would be more complex than that of PK. Knowledge of mechanism from discovery and preclinical studies are helpful for planning clinical study designs in cascade, sequential, crossover or replicate mode. The appropriate combination of biomarker identification and selection, bioanalytical methods development and validation for drugs and biomarkers, and mechanism-based PK/PD models for fitting data and predicting future clinical endpoints/outcomes provide powerful insights and guidance for effective and efficient rational drug development, toward safe and efficacious medicine for individual patients.Keywords
This publication has 58 references indexed in Scilit:
- Toxicoproteomics — a new preclinical toolDrug Discovery Today, 2002
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Methodological Issues in Pharmacokinetic-Pharmacodynamic ModellingClinical Pharmacokinetics, 1998
- The contribution of clinical pharmacology surrogates and models to drug development—a critical appraisalBritish Journal of Clinical Pharmacology, 1997
- Pharmacokinetics and Pharmacodynamics of AC137 (25,28,29 Tripro‐Amylin, Human) After Intravenous Bolus and Infusion Doses in Patients with Insulin‐Dependent DiabetesThe Journal of Clinical Pharmacology, 1996
- Surrogate Biochemical Markers: Precise Measurement for Strategic Drug and Biologics DevelopmentThe Journal of Clinical Pharmacology, 1995
- Surrogate Markers and Clinical PharmacologyThe Journal of Clinical Pharmacology, 1995
- Drugs and Endogenous Ligands Compete for Receptor OccupancyThe Journal of Clinical Pharmacology, 1994
- Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studiesEuropean Journal of Drug Metabolism and Pharmacokinetics, 1991
- Calibration is the Key to Immunoassay but the Ideal Calibrator is UnattainableScandinavian Journal of Clinical and Laboratory Investigation, 1991